Search research articles
Contact Us
Filters
Showing results (1-10 of 198) with videos related to
Page
of 20
Sort By:
Deutsches Arzteblatt International
|
July 11, 2019
In Reply
Lucie Heinzerling
Plos One
|
November 5, 2014
Therapy preferences in melanoma treatment--willingness to pay and preference of quality versus length of life of patients, physicians and healthy controls
Ramona Krammer, Lucie Heinzerling
Archives of Dermatology
|
June 19, 2008
Clinical research in cutaneous T-cell lymphoma moving forward
Wolfram Sterry, Lucie Heinzerling
Anticancer Research
|
March 2, 2018
BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma
Lisa Walter, Lucie Heinzerling
Current Opinion in Oncology
|
January 7, 2017
A review of serious adverse effects under treatment with checkpoint inhibitors
Lucie Heinzerling, Simone M Goldinger
Dermatologie (Heidelberg, Germany)
|
August 23, 2022
[Pigmented lesions of the mucosa]
Markus V Heppt, Lucie Heinzerling
Current Opinion in Oncology
|
January 4, 2021
MAPK blockade, toxicities, pathogenesis and management
Alvaro Moreira, Céleste Lebbé, Lucie Heinzerling
Cancer Medicine
|
July 11, 2020
Therapy preferences in melanoma treatment-Willingness to pay and preference of quality versus length of life of patients, physicians, healthy individuals and physicians with oncological disease
Julia Weiss, Michael Constantin Kirchberger, Lucie Heinzerling
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 15, 2026
When Does Acceptable Become Unacceptable? Toxicities of Emerging Therapies
Sydney Barned, Lucie Heinzerling, Lauren A Dalvin
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 17, 2006
Interleukin-2: a potential treatment option for postherpetic neuralgia?
Jessica Rotty, Lucie Heinzerling, Dirk Schurmann, et al.
Page
of 20
Search research articles
Search
Showing results (1-10 of 198) with videos related to
Sort By:
Page
of 20
Deutsches Arzteblatt International
|
July 11, 2019
In Reply
Lucie Heinzerling
Plos One
|
November 5, 2014
Therapy preferences in melanoma treatment--willingness to pay and preference of quality versus length of life of patients, physicians and healthy controls
Ramona Krammer, Lucie Heinzerling
Archives of Dermatology
|
June 19, 2008
Clinical research in cutaneous T-cell lymphoma moving forward
Wolfram Sterry, Lucie Heinzerling
Anticancer Research
|
March 2, 2018
BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma
Lisa Walter, Lucie Heinzerling
Current Opinion in Oncology
|
January 7, 2017
A review of serious adverse effects under treatment with checkpoint inhibitors
Lucie Heinzerling, Simone M Goldinger
Dermatologie (Heidelberg, Germany)
|
August 23, 2022
[Pigmented lesions of the mucosa]
Markus V Heppt, Lucie Heinzerling
Current Opinion in Oncology
|
January 4, 2021
MAPK blockade, toxicities, pathogenesis and management
Alvaro Moreira, Céleste Lebbé, Lucie Heinzerling
Cancer Medicine
|
July 11, 2020
Therapy preferences in melanoma treatment-Willingness to pay and preference of quality versus length of life of patients, physicians, healthy individuals and physicians with oncological disease
Julia Weiss, Michael Constantin Kirchberger, Lucie Heinzerling
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 15, 2026
When Does Acceptable Become Unacceptable? Toxicities of Emerging Therapies
Sydney Barned, Lucie Heinzerling, Lauren A Dalvin
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 17, 2006
Interleukin-2: a potential treatment option for postherpetic neuralgia?
Jessica Rotty, Lucie Heinzerling, Dirk Schurmann, et al.
Page
of 20